数量	产品目录编号	订购说明	数量 / 包装	公开价
			96-Well Plate

数量	产品目录编号	订购说明	数量 / 包装	公开价
	48-602MAG	Buffer Detection Kit for Magnetic Beads	1 Kit

528205 Sigma-AldrichPlasminogen Activator Inhibitor-1, Human, Recombinant - Calbiochem

The Plasminogen Activator Inhibitor-1, Human, Recombinant controls the biological activity of Plasminogen Activator. This small molecule/inhibitor is primarily used for Protease Inhibitors applications.

MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.

MSDS
分析证书
参考
Data Sheet

同义词: PAI-1

Primary Target: Tissue plasminogen activator (tPA) and urokinase (uPA)

View Products on Sigmaaldrich.com

Recommended Products

概述

Replacement Information

价格及供货情况

产品目录编号	库存情况	包装	数量 / 包装	价格	数量
528205-50UGCN	正在查询供货情况...... — 目前缺货有货停产少量现货供货情况有待确认登录查看库存有货目前缺货有货其余：另行通知其余：另行通知另行通知联系客户服务 Contact Customer Service 联系客户服务联系客户服务	塑胶安瓿;塑胶针药瓶	50 μg	正在检索价格...... 无法检索价格。最小订购数量为倍数 Maximum Quantity is 以订单确认为准更多信息您节约了 ()。 — Request Pricing 登录查看价格	查看库存情况 —	添加到收藏夹添加到收藏夹添加到我的收藏夹

Description
Overview	PAI-1 is the primary inhibitor of both tissue plasminogen activator (tPA) and urokinase (uPA). PAI-1 can exist either in an active inhibitory conformation or in an inactive or latent conformation. This highly purified preparation has not been exposed to denaturing conditions and has been chromatographically purified of latent material. PAI-1 is a marker for acute myocardial infarction and several thrombolytic disorders. Protects platelets against the inhibitory effects of plasma. Reported to be an important prognostic factor in breast cancer patients. PAI-1 is highly stable when stored at or below pH 6.6.
Catalogue Number	528205
Brand Family	Calbiochem®
Synonyms	PAI-1

References
References	Vaughan, D.E., et al. 1995. J. Clin. Invest. 95, 995. Dimitri, G., et al. 1993. Boll. Chim. Farmaceutico 132, 272. Janicke, F., et al. 1993. Breast Cancer Res. Treatment 24, 195. Klasser, K.J., et al. 1993. Coron. Artery Dis. 4, 713. Robbie, L.A., et al. 1993. Thromb. Hemost. 70, 307. Lawrence, D., et al. 1989. Eur. J. Biochem. 186, 523. Collen, D. and Lijnen, H.R. 1987. In The Molecular Basis of Blood Diseases (Stamatoyannopoulus, G., et al. Eds.) W.B. Saunders Ginsberg, D., et al. 1986. J. Clin. Invest. 78, 1673. Vassalli, J.D., et al. 1985. J. Cell Biol. 100, 86.

References

Vaughan, D.E., et al. 1995. J. Clin. Invest. 95, 995.
Dimitri, G., et al. 1993. Boll. Chim. Farmaceutico 132, 272.
Janicke, F., et al. 1993. Breast Cancer Res. Treatment 24, 195.
Klasser, K.J., et al. 1993. Coron. Artery Dis. 4, 713.
Robbie, L.A., et al. 1993. Thromb. Hemost. 70, 307.
Lawrence, D., et al. 1989. Eur. J. Biochem. 186, 523.
Collen, D. and Lijnen, H.R. 1987. In The Molecular Basis of Blood Diseases (Stamatoyannopoulus, G., et al. Eds.) W.B. Saunders
Ginsberg, D., et al. 1986. J. Clin. Invest. 78, 1673.
Vassalli, J.D., et al. 1985. J. Cell Biol. 100, 86.

Product Information
ATP Competitive	N
Form	Liquid
Formulation	In 150 mM NaCl, 50 mM sodium phosphate buffer, 1 mM EDTA, pH 6.6.
Reversible	N
Quality Level	MQ100

Applications

Biological Information
Primary Target	Tissue plasminogen activator (tPA) and urokinase (uPA)
Purity	≥95% by SDS-PAGE

Physicochemical Information
Cell permeable	N

Dimensions

Materials Information

Toxicological Information

Safety Information according to GHS

Safety Information

Product Usage Statements

Storage and Shipping Information
Ship Code	Dry Ice Only
Toxicity	Standard Handling
Storage	≤ -70°C
Avoid freeze/thaw	Avoid freeze/thaw
Do not freeze	Ok to freeze
Special Instructions	Following initial thaw, aliquot and freeze (-70°C).

Packaging Information

Transport Information

Supplemental Information

Specifications

Global Trade Item Number
产品目录编号	GTIN
528205-50UGCN	04055977196481

Documentation

Plasminogen Activator Inhibitor-1, Human, Recombinant - Calbiochem MSDS

职位
物料安全数据表 (MSDS)

Plasminogen Activator Inhibitor-1, Human, Recombinant - Calbiochem 分析证书

标题	批号
528205	输入批号

参考

参考信息概述
Vaughan, D.E., et al. 1995. J. Clin. Invest. 95, 995. Dimitri, G., et al. 1993. Boll. Chim. Farmaceutico 132, 272. Janicke, F., et al. 1993. Breast Cancer Res. Treatment 24, 195. Klasser, K.J., et al. 1993. Coron. Artery Dis. 4, 713. Robbie, L.A., et al. 1993. Thromb. Hemost. 70, 307. Lawrence, D., et al. 1989. Eur. J. Biochem. 186, 523. Collen, D. and Lijnen, H.R. 1987. In The Molecular Basis of Blood Diseases (Stamatoyannopoulus, G., et al. Eds.) W.B. Saunders Ginsberg, D., et al. 1986. J. Clin. Invest. 78, 1673. Vassalli, J.D., et al. 1985. J. Cell Biol. 100, 86.

参考信息概述

数据表

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision	24-August-2023 JSW
Synonyms	PAI-1
Description	Primary inhibitor of both tissue plasminogen activator (tPA) and urokinase (uPA). PAI-1 is synthesized by vascular epithelium and hepatocytes. Used as a marker for acute myocardial infarction and in the diagnosis of several thrombolytic disorders. Protects platelets against the inhibitory effects of plasma. Shown to have a role complimentary to that of α₂-anti-plasmin. Elevated levels are found in subjects with accelerated coronary artery disease. PP1 activity may limit the extent of metastasis, since uPA activity is a major contributory factor promoting dissolution of tumor matrix and basement membrane. May serve as an independent and strong prognosticator in breast cancer patients. Patients having elevated levels of PAI-1 in their primary tumors are more prone to relapse. Can exist either in an active inhibitory conformation or in an inactive or latent conformation. This highly purified preparation has not been exposed to denaturing conditions and has been chromatographically purified free of the inactive material.
Form	Liquid
Formulation	In 150 mM NaCl, 50 mM sodium phosphate buffer, 1 mM EDTA, pH 6.6.
Purity	≥95% by SDS-PAGE
Storage	Avoid freeze/thaw ≤ -70°C
Do Not Freeze	Ok to freeze
Special Instructions	Following initial thaw, aliquot and freeze (-70°C).
Toxicity	Standard Handling
References	Vaughan, D.E., et al. 1995. J. Clin. Invest. 95, 995. Dimitri, G., et al. 1993. Boll. Chim. Farmaceutico 132, 272. Janicke, F., et al. 1993. Breast Cancer Res. Treatment 24, 195. Klasser, K.J., et al. 1993. Coron. Artery Dis. 4, 713. Robbie, L.A., et al. 1993. Thromb. Hemost. 70, 307. Lawrence, D., et al. 1989. Eur. J. Biochem. 186, 523. Collen, D. and Lijnen, H.R. 1987. In The Molecular Basis of Blood Diseases (Stamatoyannopoulus, G., et al. Eds.) W.B. Saunders Ginsberg, D., et al. 1986. J. Clin. Invest. 78, 1673. Vassalli, J.D., et al. 1985. J. Cell Biol. 100, 86.

种类

Life Science Research > Inhibitors and Biochemicals > Small Molecules & Inhibitors > Proteases Inhibitors > Plasminogen Activator Inhibitors

此产品已添加到您的购物车。